Entera Bio reports Q3 net loss of $3.2 million

Entera Bio Ltd. reported a net loss of $3.2 million, or $0.07 per ordinary share, for the three months ended September 30, 2025, compared to a net loss of $3.0 million, or $0.08 per ordinary share, for the same period in 2024. Research and development expenses rose to $1.6 million from $1.5 million, mainly due to ongoing regulatory and Phase 3 preparation activities for EB613. General and administrative expenses were $1.6 million, unchanged from the prior year period. Cash and cash equivalents stood at $16.6 million as of September 30, 2025, including $8.0 million in restricted cash for the OPKO collaboration. The company expects its cash balance to fund operations through mid-third quarter 2026. Key business developments included FDA agreement on using change in total hip bone mineral density as the primary endpoint for the planned EB613 Phase 3 study, with incidence of new or worsening vertebral fractures as a key secondary endpoint. Entera also highlighted progress on its oral GLP-2 program for short bowel syndrome and oral OXM program in obesity and metabolic diseases, in partnership with OPKO Health. The next-generation EB613 remains on track for Phase 1 initiation in late 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003851), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here